Results 181 to 190 of about 60,444 (298)

Artificial Intelligence and Prostate–Breast Cancer Biology: Recent Advances in Treatments and Perspectives — A Comprehensive Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims The therapeutic limitations of conventional cancer treatment currently deployed are driving the development and creation of new nano‐drugs. Prostate cancer (PCa) is a prevalent clinical problem in older men with a significant global incidence, with 1.5 million cases reported in 2022.
Russell B. O. Ouma, Silas M. Ngari, Joshua K. Kibet   +2 more
wiley   +1 more source

Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine-Induced Myelosuppression in Australia: A Budget Impact Analysis. [PDF]

Clin Transl Sci
Ianni BD, Ali MA, Yiu CH, Tan ECK, Lu CY.   +4 more
europepmc   +1 more source

Update on cancer treatment in exotics [PDF]

, 2018
Antonissen, Gunther, Graham, Jennifer, Zehnder, Ashley   +2 more
core   +2 more sources

Myelosuppressive Chemotherapy [PDF]

, 2020
openaire   +1 more source

Glucocorticoids Combined with Methotrexate in the Treatment of Psoriasis Merged with Bullous Pemphigoid: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 3, March 2026.
Weimin Ma, Cheng Li, Haijun Miao
wiley   +1 more source

Tumor‐infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors

International Journal of Cancer, Volume 158, Issue 5, Page 1156-1165, 1 March 2026.
Abstract Tumor‐infiltrating B cells (TIBs) exhibit dual roles in the tumor microenvironment (TME) of solid tumors. While they can enhance anti‐tumor immunity through antibody production and immune activation, certain subsets—such as regulatory B cells (Bregs) and immunosuppressive plasma cells—contribute to immune evasion by secreting inhibitory ...
Zhitong Li, Ziyang Shen, Yuxiang Sun, Pengcheng Zhu, Tongyan Liu, Rong Yin   +5 more
wiley   +1 more source

Hematological Safety of Contezolid versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study

Drug Design, Development and Therapy
Wenjun Zhang,1,* Xinfeng Cai,2,* Ruigang Hou,1 Jinlin Guo,3 Ying Ma,4 Jianbang Kang,1 Xingang Li5 1Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Department of Pharmacy,
Zhang W, Cai X, Hou R, Guo J, Ma Y, Kang J, Li X   +6 more
doaj  

Pharmacogenomics of Thiopurine Drugs: A Bench-To-Bedside Success Story in Thailand. [PDF]

Clin Transl Sci
Biswas M, John S, Murad MA, Sukasem C.
europepmc   +1 more source

Day 8 monocyte and lymphocyte counts as a novel and early predictor for discontinuation in gynecologic cancer patients receiving paclitaxel and carboplatin therapy: a retrospective observational study. [PDF]

J Pharm Health Care Sci
Watanabe H, Hirai K, Komachiya H, Naito T.   +3 more
europepmc   +1 more source

Efficacy and Safety of DNV3 (a Lymphocyte‐activation Gene 3–blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open‐label, Single‐arm Clinical Trial

MedComm, Volume 7, Issue 3, March 2026.
This investigator‐initiated trial demonstrates that LAG‐3/PD‐1 dual blockade (DNV3 + toripalimab) combined with chemotherapy achieves a 44.4% overall response rate (ORR) in advanced melanoma, showing particular efficacy in anti‐PD‐(L)1‐resistant patients (42.9% ORR, 7.36‐month median PFS), treatment‐naïve mucosal melanoma (50.0% ORR), and those with ...
Jing Lin, Lizhu Chen, Ling Chen, Dingyi Wang, Yuping Lu, Huishan Zhang, Ping Chen, Wei Yan, Zuoxiang Xiao, Yu Chen   +9 more
wiley   +1 more source